Dr. Reddy’s Laboratories has received an Establishment Inspection Report (EIR) from the US Food and Drug Administration (USFDA) as closure of audit for Miryalaguda facility. Miryalaguda plant supplies active ingredients for company’s captive consumption as well as for its customers.
Earlier in February, the USFDA had conducted an audit of API manufacturing plant at Miryalaguda, wherein the company was issued a form 483 with three observations for the said facility.
Dr. Reddy’s Laboratories is a multinational pharmaceutical company based in Hyderabad, Telangana in India. It manufactures and markets a wide range of pharmaceuticals in India and overseas.
